Mesoblast (NASDAQ:MESO) Shares Pass Below 50 Day Moving Average – Time to Sell?

Shares of Mesoblast Limited (NASDAQ:MESO) passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $16.19 and traded as low as $15.77. Mesoblast shares last traded at $15.80, with a volume of 456,921 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Mesoblast currently has a consensus rating of “Hold”.

Mesoblast Price Performance

The stock has a market capitalization of $2.04 billion, a P/E ratio of -17.95 and a beta of 2.19. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.41 and a current ratio of 1.58. The firm has a 50-day moving average price of $16.19 and a 200 day moving average price of $16.88.

Mesoblast (NASDAQ:MESO) last released its earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share for the quarter. The company had revenue of $25.67 million during the quarter. On average, analysts expect that Mesoblast Limited will post -0.7 EPS for the current year.

Institutional Trading of Mesoblast

Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in shares of Mesoblast by 4.2% in the fourth quarter. Legal & General Group Plc now owns 679,023 shares of the company’s stock valued at $12,237,000 after acquiring an additional 27,607 shares during the period. Goldman Sachs Group Inc. bought a new stake in shares of Mesoblast in the first quarter worth about $3,209,000. Bank of America Corp DE increased its holdings in Mesoblast by 791.7% during the 3rd quarter. Bank of America Corp DE now owns 111,459 shares of the company’s stock valued at $1,796,000 after purchasing an additional 98,960 shares during the period. Rialto Wealth Management LLC bought a new position in Mesoblast during the 4th quarter valued at approximately $839,000. Finally, Brooklyn Investment Group purchased a new stake in Mesoblast in the 3rd quarter worth approximately $655,000. Hedge funds and other institutional investors own 1.43% of the company’s stock.

Mesoblast Company Profile

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.